Practice Tools

Practical resources to support your canine OA patients

Our library is designed to connect you with the latest insight, medical tools, educational opportunities and activities to support the veterinary profession in managing canine osteoarthritis (OA) and implementing the effective use of Adequan® Canine (polysulfated glycosaminoglycan). Take a look at the links below and choose what best fits your search for information.

Clinical Studies Canine red ball dog

Technical Bulletin: A Disease-Modifying Osteoarthritis Drug

Adequan® Canine is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in a dog’s synovial joints.1 This technical bulletin will help you learn more about the unique characteristics of Adequan® Canine and the distinct advantages it may provide in slowing the progression of OA in dogs.


DMOAD Bulletin

1. Adequan® Canine (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.

Infographic: Playful pup or couch potato?

This infographic is a visually engaging way to introduce clients to the early signs of canine OA and what to look for. It can be displayed as a poster in your waiting area, exam room or printed and handed to clients.

Printable PDF

Digital Brochure: Adequan® Canine Pet Parent Brochure


This digital brochure can help you discuss with clients the early signs of canine osteoarthritis and why it is important to start the discussion early to help maintain joint mobility.

Brochure PDF English

Brochure PDF Spanish

Adequan® Canine Features-Benefits Educational Flyer

This digital flyer can help you discuss the primary features and benefits of using Adequan® Canine (polysulfated glycosaminoglycan) for treating canine osteoarthritis in dogs with your team and your pet owners. The difference between feeling better and getting better.®

For the best interactive experience, save the PDF onto your device.

Printable PDF

Adequan® Canine Educational Treatment Tool

This tool can help guide your discussions with clients about your recommendation of Adequan® Canine. It includes an area to outline treatment dates and note multi-modal plans for their dog.

For the best interactive experience, save the PDF onto your device.

Printable PDF

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

CANINE VETERINARY
PROFESSIONAL		 DOG OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up Press Room
ABOUT ADEQUAN® CANINE
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
All trademarks are the property of American Regent, Inc
© 2022, American Regent, Inc.
PP-AC-US-0102 (v6.0) 04/2022